Chapter

Pioneering use of gene therapy for pain

Vadym Biloshytsky and Roman Cregg

in Landmark Papers in Pain

Published on behalf of Oxford University Press

Published in print July 2018 | ISBN: 9780198834359
Published online September 2018 | e-ISBN: 9780191800924 | DOI: https://dx.doi.org/10.1093/med/9780198834359.003.0083

Series: Landmark Papers In

Pioneering use of gene therapy for pain

More Like This

Show all results sharing these subjects:

  • Pain Medicine
  • Pain Management and Palliative Pharmacology

GO

Show Summary Details

Preview

The landmark paper discussed in this chapter is ‘Gene therapy for pain: Results of a Phase I clinical trial’, published by Fink et al. in 2011. In this study, the first of its kind, researchers studied the efficacy and safety of a modified herpes simplex virus (HSV) vector used to deliver PENK, which encodes proenkephalin, which is cleaved into the enkephalin peptides Met-enkephalin and Leu-enkephalin, which induce analgesia by acting on opioid receptors. The development of the HSV vector was based in part on results studies in which adenovirus, adeno-associated virus, or non-viral vectors were used to overexpress genes. Overexpression of a variety of large molecules leads to a reduction in pain-related behaviour in animals. Gene therapy in the treatment of chronic pain seems to offer a promising alternative to systemic or highly invasive therapies. However, additional research is needed to determine the safety, effectiveness, and cost-efficiency of this approach.

Chapter.  1130 words. 

Subjects: Pain Medicine ; Pain Management and Palliative Pharmacology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.